• Something wrong with this record ?

Aurora A Functional Single Nucleotide Polymorphism (SNP) Correlates With Clinical Outcome in Patients With Advanced Solid Tumors Treated With Alisertib, an Investigational Aurora A Kinase Inhibitor

H. Niu, H. Shin, F. Gao, J. Zhang, B. Bahamon, H. Danaee, B. Melichar, RJ. Schilder, RL. Coleman, G. Falchook, A. Adenis, K. Behbakht, A. DeMichele, EC. Dees, K. Perez, U. Matulonis, P. Sawrycki, D. Huebner, J. Ecsedy,

. 2017 ; 25 (-) : 50-57. [pub] 20171016

Language English Country Netherlands

Document type Clinical Trial, Phase I, Clinical Trial, Phase II, Journal Article, Multicenter Study

Persistent link   https://www.medvik.cz/link/bmc18033578

BACKGROUND: Alisertib (MLN8237) is an investigational, oral, selective Aurora A kinase inhibitor. Aurora A contains two functional single nucleotide polymorphisms (SNPs; codon 31 [F/I] and codon 57 [V/I]) that lead to functional changes. This study investigated the prognostic and predictive significance of these SNPs. METHODS: This study evaluated associations between Aurora A SNPs and overall survival (OS) in The Cancer Genome Atlas (TCGA) database. The Aurora A SNPs were also evaluated as predictive biomarkers for clinical outcomes to alisertib in two phase 2 studies (NCT01045421 and NCT01091428). Aurora A SNP genotyping was obtained from 85 patients with advanced solid tumors receiving single-agent alisertib and 122 patients with advanced recurrent ovarian cancer treated with alisertib plus weekly paclitaxel (n=62) or paclitaxel alone (n=60). Whole blood was collected prior to treatment and genotypes were analyzed by PCR. FINDINGS: TCGA data suggested prognostic significance for codon 57 SNP; solid tumor patients with VV and VI alleles had significantly reduced OS versus those with II alleles (HR 1.9 [VI] and 1.8 [VV]; p<0.0001). In NCT01045421, patients carrying the VV alleles at codon 57 (n=53, 62%) had significantly longer progression-free survival (PFS) than patients carrying IV or II alleles (n=32, 38%; HR 0.5; p=0.0195). In NCT01091428, patients with the VV alleles at codon 57 who received alisertib plus paclitaxel (n=47, 39%) had a trend towards improved PFS (7.5months) vs paclitaxel alone (n=32, 26%; 3.8months; HR 0.618; p=0.0593). In the paclitaxel alone arm, patients with the VV alleles had reduced PFS vs modified intent-to-treat (mITT) patients (3.8 vs 5.1months), consistent with the TCGA study identifying the VV alleles as a poor prognostic biomarker. No significant associations were identified for codon 31 SNP from the same data set. INTERPRETATION: These findings suggest that Aurora A SNP at codon 57 may predict disease outcome and response to alisertib in patients with solid tumors. Further investigation is warranted.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18033578
003      
CZ-PrNML
005      
20181026103214.0
007      
ta
008      
181008s2017 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ebiom.2017.10.015 $2 doi
035    __
$a (PubMed)29122619
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Niu, Huifeng $u Millennium Pharmaceuticals, Inc., Cambridge, MA, USA. Electronic address: huifeng.niu@takeda.com.
245    10
$a Aurora A Functional Single Nucleotide Polymorphism (SNP) Correlates With Clinical Outcome in Patients With Advanced Solid Tumors Treated With Alisertib, an Investigational Aurora A Kinase Inhibitor / $c H. Niu, H. Shin, F. Gao, J. Zhang, B. Bahamon, H. Danaee, B. Melichar, RJ. Schilder, RL. Coleman, G. Falchook, A. Adenis, K. Behbakht, A. DeMichele, EC. Dees, K. Perez, U. Matulonis, P. Sawrycki, D. Huebner, J. Ecsedy,
520    9_
$a BACKGROUND: Alisertib (MLN8237) is an investigational, oral, selective Aurora A kinase inhibitor. Aurora A contains two functional single nucleotide polymorphisms (SNPs; codon 31 [F/I] and codon 57 [V/I]) that lead to functional changes. This study investigated the prognostic and predictive significance of these SNPs. METHODS: This study evaluated associations between Aurora A SNPs and overall survival (OS) in The Cancer Genome Atlas (TCGA) database. The Aurora A SNPs were also evaluated as predictive biomarkers for clinical outcomes to alisertib in two phase 2 studies (NCT01045421 and NCT01091428). Aurora A SNP genotyping was obtained from 85 patients with advanced solid tumors receiving single-agent alisertib and 122 patients with advanced recurrent ovarian cancer treated with alisertib plus weekly paclitaxel (n=62) or paclitaxel alone (n=60). Whole blood was collected prior to treatment and genotypes were analyzed by PCR. FINDINGS: TCGA data suggested prognostic significance for codon 57 SNP; solid tumor patients with VV and VI alleles had significantly reduced OS versus those with II alleles (HR 1.9 [VI] and 1.8 [VV]; p<0.0001). In NCT01045421, patients carrying the VV alleles at codon 57 (n=53, 62%) had significantly longer progression-free survival (PFS) than patients carrying IV or II alleles (n=32, 38%; HR 0.5; p=0.0195). In NCT01091428, patients with the VV alleles at codon 57 who received alisertib plus paclitaxel (n=47, 39%) had a trend towards improved PFS (7.5months) vs paclitaxel alone (n=32, 26%; 3.8months; HR 0.618; p=0.0593). In the paclitaxel alone arm, patients with the VV alleles had reduced PFS vs modified intent-to-treat (mITT) patients (3.8 vs 5.1months), consistent with the TCGA study identifying the VV alleles as a poor prognostic biomarker. No significant associations were identified for codon 31 SNP from the same data set. INTERPRETATION: These findings suggest that Aurora A SNP at codon 57 may predict disease outcome and response to alisertib in patients with solid tumors. Further investigation is warranted.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a alely $7 D000483
650    _2
$a aurora kinasa A $x genetika $7 D064096
650    _2
$a azepiny $x aplikace a dávkování $x škodlivé účinky $7 D001381
650    _2
$a nádorové biomarkery $x genetika $7 D014408
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a staging nádorů $7 D009367
650    _2
$a nádory $x farmakoterapie $x genetika $x patologie $7 D009369
650    _2
$a paclitaxel $x aplikace a dávkování $x škodlivé účinky $7 D017239
650    _2
$a jednonukleotidový polymorfismus $7 D020641
650    _2
$a inhibitory proteinkinas $x aplikace a dávkování $7 D047428
650    _2
$a pyrimidiny $x aplikace a dávkování $x škodlivé účinky $7 D011743
650    _2
$a výsledek terapie $7 D016896
655    _2
$a klinické zkoušky, fáze I $7 D017426
655    _2
$a klinické zkoušky, fáze II $7 D017427
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Shin, Hyunjin $u Millennium Pharmaceuticals, Inc., Cambridge, MA, USA.
700    1_
$a Gao, Feng $u Millennium Pharmaceuticals, Inc., Cambridge, MA, USA.
700    1_
$a Zhang, Jacob $u Millennium Pharmaceuticals, Inc., Cambridge, MA, USA.
700    1_
$a Bahamon, Brittany $u Millennium Pharmaceuticals, Inc., Cambridge, MA, USA.
700    1_
$a Danaee, Hadi $u Millennium Pharmaceuticals, Inc., Cambridge, MA, USA.
700    1_
$a Melichar, Bohuslav $u Department of Oncology, Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic.
700    1_
$a Schilder, Russell J $u Department of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA, USA.
700    1_
$a Coleman, Robert L $u The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
700    1_
$a Falchook, Gerald $u Sarah Cannon Research Institute at HealthONE, Denver, CO, USA.
700    1_
$a Adenis, Antoine $u Centre Oscar Lambret, Lille, France.
700    1_
$a Behbakht, Kian $u Department of Gynecologic Oncology, University of Colorado School of Medicine, Aurora, CO, USA.
700    1_
$a DeMichele, Angela $u Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA.
700    1_
$a Dees, Elizabeth Claire $u UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.
700    1_
$a Perez, Kimberly $u Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
700    1_
$a Matulonis, Ursula $u Gynecologic Oncology Program, Dana-Farber Cancer Institute, Boston, MA, USA.
700    1_
$a Sawrycki, Piotr $u Department of Oncology and Chemotherapy, L. Rydygiera District Hospital, Torun, Poland.
700    1_
$a Huebner, Dirk $u Millennium Pharmaceuticals, Inc., Cambridge, MA, USA.
700    1_
$a Ecsedy, Jeffrey $u Millennium Pharmaceuticals, Inc., Cambridge, MA, USA.
773    0_
$w MED00190061 $t EBioMedicine $x 2352-3964 $g Roč. 25, č. - (2017), s. 50-57
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29122619 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20181008 $b ABA008
991    __
$a 20181026103725 $b ABA008
999    __
$a ok $b bmc $g 1339510 $s 1030572
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 25 $c - $d 50-57 $e 20171016 $i 2352-3964 $m EBioMedicine $n EBioMedicine $x MED00190061
LZP    __
$a Pubmed-20181008
Back

Find record

Citation metrics

Archiving options